Taysha Gene Therapies, Inc. (TSHA)
| Market Cap | 42.46M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -160.68M |
| Shares Out | 62.44M |
| EPS (ttm) | -4.12 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 560,027 |
| Open | 0.683 |
| Previous Close | 0.700 |
| Day's Range | 0.650 - 0.756 |
| 52-Week Range | 0.650 - 7.077 |
| Beta | 1.22 |
| Analysts | Buy |
| Price Target | 7.31 (+975.0%) |
| Earnings Date | May 15, 2023 |
About TSHA
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies,... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 20 analysts, the average rating for TSHA stock is "Buy." The 12-month stock price forecast is $7.31, which is an increase of 975.00% from the latest price.
News
Taysha Gene Therapies to Release Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call and Webcast on March 28
DALLAS, March 15, 2023 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene t...
Taysha Gene Therapies Provides Update on TSHA-120 Program in Giant Axonal Neuropathy and a 2023 Corporate Outlook
Type B end-of-Phase 2 meeting with U.S. Food and Drug Administration (FDA) provided additional clarity for TSHA-120 for the treatment of giant axonal neuropathy (GAN) ultra-rare disease program - FDA...
Taysha Gene Therapies Announces Executive Leadership Changes
Chair of the Board of Directors, Sean P. Nolan, appointed Chief Executive Officer
Taysha Gene Therapies, Inc. (TSHA) Could Find Support Soon, Here's Why You Should Buy the Stock Now
Taysha Gene Therapies, Inc. (TSHA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisi...
Taysha Gene Therapies to Participate in JMP Securities Hematology and Oncology Summit
DALLAS, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene the...
Taysha Gene Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
$50 million strategic investment from Astellas Pharma to support development of TSHA-120 in giant axonal neuropathy (GAN) and TSHA-102 in Rett syndrome
Taysha Gene Therapies to Release Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 8
DALLAS, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene the...
Taysha Announces Pricing of Public Offering of Common Stock
DALLAS, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (“Taysha”), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-bas...
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock
DALLAS, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene the...
What Is Going on With Taysha Gene (TSHA) Stock Today?
Taysha Gene Therapies (NASDAQ: TSHA) jumped 50% overnight after Japan's Astellas Pharma (OTCMKTS: ALPMY) bought 15% of the company and exclusive marketing rights to its genetic therapies. Taysha is ...
Taysha Gene Therapies to Host Conference Call to Discuss Astellas Pharma's Strategic Investment to Support the Development of Taysha's AAV-based Gene Therapy Programs
Conference call and webcast on Tuesday, October 25 at 8:00 AM ET Conference call and webcast on Tuesday, October 25 at 8:00 AM ET
Astellas and Taysha Gene Therapies Announce Strategic Investment to Support Development of Taysha's AAV-based Gene Therapy Programs
- Taysha Gene Therapies is an emerging leader in the development of AAV gene therapies; new collaboration aimed at enhancing development of two of Taysha's novel product candidates for rare monogenic ...
Taysha Gene Therapies Announces Presentations at the Upcoming 29th Annual Meeting of the European Society of Gene & Cell Therapy (ESGCT)
DALLAS, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene the...
Taysha Gene Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update
TSHA-120 treated patients in GAN demonstrated durable improvement and recoverability of sensory nerve amplitude potential (SNAP), a definitive clinical endpoint, compared to natural history
Taysha Gene Therapies to Release Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11
DALLAS, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene the...
Taysha Gene Therapies to Participate in Upcoming August Investor Conferences
BTIG Biotechnology Conference on August 8, 2022 at 12:00 pm ET
Taysha Gene Therapies to Participate in Upcoming William Blair Biotech Focus Conference 2022
President, Founder and Chief Executive Officer to participate in “AAV Gene Therapy: Delivery and Beyond” panel discussion on Wednesday, July 13, 2022 at 10:00 am ET President, Founder and Chief Execut...
Taysha Gene Therapies Announces Annual Stockholder Meeting
The Annual Stockholder Meeting on Friday, June 17, 2022 at 10 am ET The Annual Stockholder Meeting on Friday, June 17, 2022 at 10 am ET
Taysha Gene Therapies to Participate in Upcoming June Investor Conferences and Convention
Jefferies Healthcare Conference on June 8, 2022 at 9:30 am ET
Taysha Gene Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update
Initiated clinical development of TSHA-102 for Rett Syndrome under recently approved Clinical Trial Application (CTA) with preliminary Phase 1/2 data expected by year-end 2022
Taysha Gene Therapies to Release First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 16
DALLAS, May 11, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene ther...
Taysha Gene Therapies Announces Presentations at the Upcoming 25th Annual Meeting of the American Society of Gene & Cell Therapy
DALLAS, May 10, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene ther...
Taysha Gene Therapies Receives Orphan Drug Designation from the European Commission for TSHA-120 for the Treatment of Giant Axon Neuropathy (GAN)
Clinical efficacy data for TSHA-120 provide quantitative evidence of long-term durability across all therapeutic dose cohorts with a 10-point improvement in mean change in MFM32 by Year 3 compared to ...
Taysha Gene Therapies Announces Oral Presentations at the Upcoming 2022 IRSF Rett Syndrome Scientific Symposium and the ASCEND National Summit
DALLAS, April 25, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene th...
Taysha Gene Therapies to Participate in Upcoming Chardan Genetic Medicines and Cell Therapy Manufacturing Summit
Chief Executive Officer, Chief Technical Officer, Chief Medical Officer and Head of Research and Development and Senior Vice President of Manufacturing to participate in a panel discussion at the Char...